Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853360 | 1.00 | OPRM1 (0.53) | OPRM1CHRM2CHRM3MEN1KMT2A | |
| SCHEMBL13853358 | 0.83 | OPRM1 (0.60) | OPRM1CHRM2CHRM3CCR5 | |
| SCHEMBL4199351 | 0.83 | OPRM1 (0.60) | OPRM1CHRM2CHRM3CCR5 | |
| SCHEMBL4193608 | 0.80 | MEN1 (0.52) | OPRM1MEN1KMT2ALMNACCR5 | |
| SCHEMBL13853362 | 0.80 | MEN1 (0.52) | OPRM1MEN1KMT2ALMNACCR5 | |
| SCHEMBL4201992 | 0.80 | CCR5 (0.53) | OPRM1MEN1KMT2ACCR5 | |
| SCHEMBL13853364 | 0.80 | CCR5 (0.53) | OPRM1MEN1KMT2ACCR5 | |
| SCHEMBL4124844 | 0.80 | OPRM1 (0.70) | OPRM1CHRM2CHRM3CCR5PKM | |
| SCHEMBL7242578 | 0.79 | FUCA1 (0.50) | OPRM1S1PR1S1PR5KDM4EGRIN2B | |
| SCHEMBL3527474 | 0.75 | GRIN2B (0.45) | OPRM1S1PR1S1PR5KDM4EGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124635-A1 | CHEMICAL COMPOUNDS | PFIZER INC. (GB) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124635-A1 | CHEMICAL COMPOUNDS | CCR5, CXCR3, CCR2 | OPRM1 60/4885CHRM2 134/4885CHRM3 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.